AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28551645 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with uracil‐tegafur
Number of subjects: 229
Study 28551645 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage II disease
Number of subjects: 229
Study 26170126 — intervention group
Group type: EXPERIMENTAL
Intervention: Aveeno® lotion
Number of subjects: 160
Study 26170126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprobase® cream
Number of subjects: 160
Study 26170126 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublebase® gel
Number of subjects: 160
Study 26170126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromol® ointment
Number of subjects: 160
Study 23817921 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelin peptide skin patch (1 mg)
Number of subjects: 30
Study 23817921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21113833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight session protocol
Number of subjects: 137
Study 21113833 — intervention group
Group type: COMPARATOR
Intervention: Four session protocol
Number of subjects: 137
Study 18856126 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative approach (randomized controlled clinical trial)
Number of subjects: 0
Study 18856126 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative approach
Number of subjects: 0
Study 16801838 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic prednisolone (15 mg/5 ml)
Number of subjects: 188
Study 16801838 — intervention group
Group type: COMPARATOR
Intervention: Orapred (15 mg/5 ml)
Number of subjects: 188
Study 12970289 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human PTH-(1-34) (PTH)
Number of subjects: 27
Study 12970289 — intervention group
Group type: COMPARATOR
Intervention: Oral calcitriol and calcium
Number of subjects: 27
Study 10656170 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (600 mg bid)
Number of subjects: 30
Study 10656170 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (20 mg qd)
Number of subjects: 30
Study 10656170 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 30
Study 10656170 — intervention group
Group type: COMPARATOR
Intervention: simvastatin
Number of subjects: 30
Study 8683863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy, daily subcutaneous doses of 2.5, 5.0 or 7.5 micrograms/kg for 7 or 14 days
Number of subjects: 4
Study 8683863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy with co-administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (Epo)
Number of subjects: 4
Study 8683863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy with sequential administration of G-CSF and Epo two weeks after IL-3
Number of subjects: 4
Study 8683863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-3 (IL-3) therapy
Number of subjects: 4
Study 1861931 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol syrup (2 mg)
Number of subjects: 65
Study 1861931 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol syrup (10 mg)
Number of subjects: 65
Study 1861931 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 65
Study 6409599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinromide (1,200 to 4,800 mg/day)
Number of subjects: 28
Study 6409599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 4013351 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg spironolactone + 20 mg furosemide (SF)
Number of subjects: 22
Study 4013351 — intervention group
Group type: COMPARATOR
Intervention: 50 mg spironolactone + 5 mg butizide (SB)
Number of subjects: 22
Study 29104022 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning intervention (physical activity combined with academic content)
Number of subjects: 1129
Study 29104022 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary classroom)
Number of subjects: 1129
Study 27123570 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination 0.05 ml intradermally in the upper left arm within seven days of birth
Number of subjects: 4262
Study 27123570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4262
Study 24725468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed value contingency management (three £10 vouchers)
Number of subjects: 210
Study 24725468 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating value contingency management (£5, £10, and £15 vouchers)
Number of subjects: 210
Study 24725468 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no incentive)
Number of subjects: 210
Study 22733474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus spironolactone
Number of subjects: 17
Study 22733474 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone alone
Number of subjects: 17
Study 22733474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus irbesartan
Number of subjects: 17
Study 19949016 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise program (n = 29)
Number of subjects: 57
Study 19949016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 28)
Number of subjects: 57
Study 18523846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (A1)
Number of subjects: 64
Study 18523846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (A2)
Number of subjects: 64
Study 18523846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection (B1)
Number of subjects: 64
Study 18523846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided extracorporeal shock wave therapy (B2)
Number of subjects: 64
Study 15867200 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/LV/bevacizumab (5 mg/kg once every 2 weeks)
Number of subjects: 490
Study 15867200 — intervention group
Group type: COMPARATOR
Intervention: FU/LV or IFL (control group)
Number of subjects: 490
Study 12705648 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucofiltration of arterial blood throughout cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 12705648 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucofiltration of a part of the venous return blood in the rewarming phase during CPB
Number of subjects: 40
Study 12705648 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucofiltration of residual heart‐lung machine blood during transfusion into the patient after CPB
Number of subjects: 40
Study 12705648 — intervention group
Group type: COMPARATOR
Intervention: Control group without leucofiltration
Number of subjects: 40
Study 10685270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal-synchronized intermittent mandatory ventilation (NP-SIMV)
Number of subjects: 41
Study 10685270 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal continuous positive airway pressure (NPCPAP)
Number of subjects: 41
Study 8932042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized curriculum (experimental group)
Number of subjects: 150
Study 8932042 — intervention group
Group type: COMPARATOR
Intervention: Routine-care control group
Number of subjects: 150
Study 1756919 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic microwave coagulation
Number of subjects: 127
Study 1756919 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerosis
Number of subjects: 127
Study 6643056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil treatment following curettage
Number of subjects: 0
Study 6643056 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30451307 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept treatment for 6 months
Number of subjects: 12
Study 30451307 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4/CD8 ratio
Number of subjects: 12
Study 29546527 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours bed rest after intrathecal chemotherapy
Number of subjects: 390
Study 29546527 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 hours bed rest after intrathecal chemotherapy
Number of subjects: 390
Study 29546527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 hours bed rest after intrathecal chemotherapy
Number of subjects: 390
Study 25981194 — intervention group
Group type: EXPERIMENTAL
Intervention: Online gross anatomy examinations
Number of subjects: 45
Study 25981194 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'steeplechase' examinations
Number of subjects: 45
Study 24121245 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback (RTF) training
Number of subjects: 22
Study 24121245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 22
Study 22387716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa group
Number of subjects: 26
Study 22387716 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 26
Study 22387716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 20542806 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 208
Study 20542806 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 208
Study 17667198 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilatory assistance (NIV)
Number of subjects: 8
Study 17667198 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing test (SBT)
Number of subjects: 8
Study 15652898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 82
Study 11838000 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d n-3 fatty acids
Number of subjects: 223
Study 11838000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 9543078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg/daily)
Number of subjects: 20
Study 7922063 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 300
Study 7922063 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study 3289830 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen CR 1000 mg
Number of subjects: 100
Study 3289830 — intervention group
Group type: COMPARATOR
Intervention: isoxicam 200 mg
Number of subjects: 100
Study 4568356 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium 300 mg daily
Number of subjects: 31
Study 4568356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30101320 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-F (Parent Training for Feeding problems)
Number of subjects: 42
Study 30101320 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 42
Study 27928704 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1000 mg/day co-administered with piperine 10 mg/day)
Number of subjects: 118
Study 25646817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine regimen
Number of subjects: 0
Study 25646817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study 25646817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25129247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol (DT) 12.5 mg
Number of subjects: 0
Study 25129247 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 0
Study 23251152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index carbohydrates (Group 2)
Number of subjects: 107
Study 23251152 — intervention group
Group type: COMPARATOR
Intervention: All types of carbohydrates (Group 1)
Number of subjects: 107
Study 19304392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical pain severity
Number of subjects: 75
Study 19304392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 75
Study 19304392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related fears of movement
Number of subjects: 75
Study 19304392 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 75
Study 19304392 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting pain-related psychological risk factors
Number of subjects: 75
Study 17378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (maximum dose of 40 mg/d)
Number of subjects: 44
Study 17378918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 44
Study 14749544 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (20 mg PO of prednisone)
Number of subjects: 24
Study 14749544 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (20 mg PO of prednisone)
Number of subjects: 24
Study 14749544 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated data sets
Number of subjects: 24
Study 14749544 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioequivalence assessment of prednisone formulations
Number of subjects: 24
Study 11413083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) - 4-hour intravenous infusion
Number of subjects: 66
Study 11413083 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 66
Study 9068327 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms kg‐1
Number of subjects: 20
Study 9068327 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 20
Study 8111502 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet for 6 weeks
Number of subjects: 383
Study 8111502 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet for 18 weeks
Number of subjects: 383
Study 8111502 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Step‐One Diet
Number of subjects: 383
Study 3518528 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (1.0 mg/kg)
Number of subjects: 39
Study 3518528 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (3.0 mg/kg)
Number of subjects: 39
Study 31952923 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine (2·5×10^4 PFU, 2×10^5 PFU, 1·8×10^6 PFU)
Number of subjects: 39
Study 31952923 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine
Number of subjects: 39
Study 31952923 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVN4CT1-EBOVGP1 vaccine (high-dose cohort)
Number of subjects: 39
Study 31952923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29951651 — intervention group
Group type: EXPERIMENTAL
Intervention: NC containing red yeast rice, policosanols, resveratrol and chromium picolinate (10 mg of monacolin K)
Number of subjects: 30
Study 29951651 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (Control)
Number of subjects: 30
Study 28390210 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alumina toothpaste
Number of subjects: 169
Study 28390210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% alumina toothpaste
Number of subjects: 169
Study 28390210 — intervention group
Group type: COMPARATOR
Intervention: Reference toothpaste (silica-based)
Number of subjects: 169
Study 24831577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (40 mg before treatment plus maintenance for 7 days)
Number of subjects: 185
Study 24831577 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (placebo before treatment plus 10 mg maintenance for 7 days)
Number of subjects: 185
Study 24831577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin
Number of subjects: 185
Study 24831577 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rosuvastatin
Number of subjects: 185
Study 21911336 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical activity counseling (face-to-face meeting followed by telephone contacts every 4 months for 2 years)
Number of subjects: 632
Study 21911336 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical activity counseling
Number of subjects: 632
Study 20211830 — intervention group
Group type: EXPERIMENTAL
Intervention: Day shift
Number of subjects: 480
Study 20211830 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle bay
Number of subjects: 480
Study 20211830 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrants at the back of a bay
Number of subjects: 480
Study 20211830 — intervention group
Group type: EXPERIMENTAL
Intervention: All sound levels
Number of subjects: 480
Study 18027030 — intervention group
Group type: EXPERIMENTAL
Intervention: Knot-tying training on a VR simulator (Group A)
Number of subjects: 20
Study 18027030 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 20
Study 16118813 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to prescribed antiretroviral therapy
Number of subjects: 35
Study 16118813 — intervention group
Group type: EXPERIMENTAL
Intervention: Long periods of time without intake adherence measures
Number of subjects: 35
Study 12834992 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-drinking exposures
Number of subjects: 444
Study 12834992 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious service attendance
Number of subjects: 444
Study 12834992 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 444
Study 10395118 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Sampling Model (LSM) for Drug A
Number of subjects: 15
Study 10395118 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Sampling Model (LSM) for Drug B
Number of subjects: 15
Study 8879370 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus IFN (arm B)
Number of subjects: 105
Study 8879370 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (arm A)
Number of subjects: 105
Study 8284116 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐OMP
Number of subjects: 35
Study 8284116 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 35
Study 3737785 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 4
Study 3737785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 28804809 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Patient Education (TPE) program
Number of subjects: 0
Study 28804809 — intervention group
Group type: EXPERIMENTAL
Intervention: TPE program
Number of subjects: 0
Study 28804809 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific assessment criterion (subscale 9 of the Brief Pain Inventory)
Number of subjects: 0
Study 26785220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg GSK2586184 twice daily
Number of subjects: 60
Study 26785220 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GSK2586184 twice daily
Number of subjects: 60
Study 26785220 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg GSK2586184 twice daily
Number of subjects: 60
Study 26785220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24697586 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultraviolet A (BB-UVA) at 10 or 15 J/cm² per session
Number of subjects: 61
Study 24697586 — intervention group
Group type: COMPARATOR
Intervention: Psoralen + UVA (PUVA)
Number of subjects: 61
Study 22632852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture
Number of subjects: 43
Study 22632852 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43
Study 22632852 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 19752609 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 core biopsy
Number of subjects: 244
Study 19752609 — intervention group
Group type: COMPARATOR
Intervention: 15 core biopsy
Number of subjects: 244
Study 17323185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day)
Number of subjects: 121
Study 17323185 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (2.5 mg/day)
Number of subjects: 121
Study 15062882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigar smoking
Number of subjects: 12
Study 11133320 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM spatial normalization method
Number of subjects: 0
Study 11133320 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR (spatial transformation algorithm for registration)
Number of subjects: 0
Study 11133320 — intervention group
Group type: EXPERIMENTAL
Intervention: Atlas-based adaptive smoothing method
Number of subjects: 0
Study 11133320 — intervention group
Group type: COMPARATOR
Intervention: Gaussian filtering method
Number of subjects: 0
Study 10168532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride (10(-3)M)
Number of subjects: 20
Study 10168532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized amiloride (10(-2)M)
Number of subjects: 20
Study 10168532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7959995 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy (Group III)
Number of subjects: 0
Study 7959995 — intervention group
Group type: COMPARATOR
Intervention: No diuretic therapy (Group II)
Number of subjects: 0
Study 7959995 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group I)
Number of subjects: 0
Study 2884723 — intervention group
Group type: EXPERIMENTAL
Intervention: Salazosulfapyridine (SI) at a dose of 2 g/day
Number of subjects: 60
Study 2884723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2884723 — intervention group
Group type: EXPERIMENTAL
Intervention: Salazosulfapyridine (SI)
Number of subjects: 60
Study 28198205 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mg / day total MCs
Number of subjects: 59
Study 28198205 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg / day total MCs
Number of subjects: 59
Study 28198205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26268815 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 10 mg/kg i.v. every 2 weeks until week 10
Number of subjects: 100